EOVIST Drug Patent Profile
✉ Email this page to a colleague
When do Eovist patents expire, and what generic alternatives are available?
Eovist is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in EOVIST is gadoxetate disodium. One supplier is listed for this compound. Additional details are available on the gadoxetate disodium profile page.
Summary for EOVIST
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 14 |
| Clinical Trials: | 14 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EOVIST |
| What excipients (inactive ingredients) are in EOVIST? | EOVIST excipients list |
| DailyMed Link: | EOVIST at DailyMed |
Recent Clinical Trials for EOVIST
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bracco Diagnostics, Inc | Phase 4 |
| University of Colorado, Denver | Phase 4 |
| National Cancer Institute (NCI) | Phase 4 |
Pharmacology for EOVIST
| Drug Class | Gadolinium-based Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for EOVIST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | EOVIST | gadoxetate disodium | SOLUTION;INTRAVENOUS | 022090-001 | Jul 3, 2008 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bayer Hlthcare | EOVIST | gadoxetate disodium | SOLUTION;INTRAVENOUS | 022090-002 | Feb 4, 2013 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EOVIST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | EOVIST | gadoxetate disodium | SOLUTION;INTRAVENOUS | 022090-002 | Feb 4, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bayer Hlthcare | EOVIST | gadoxetate disodium | SOLUTION;INTRAVENOUS | 022090-001 | Jul 3, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bayer Hlthcare | EOVIST | gadoxetate disodium | SOLUTION;INTRAVENOUS | 022090-001 | Jul 3, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EOVIST
See the table below for patents covering EOVIST around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| German Democratic Republic | 296276 | Derivatisierte DTPA-Komplexe, diese Verbindungen enthaltende pharmazeutische Mittel, ihre Verwendung und Verfahren zu deren Herstellung | ⤷ Try a Trial |
| New Zealand | 234295 | 3,6,9-TRIAZA-3,6,9-TRIS(CARBOXYMETHYL)UNDECANEDIOIC ACID DERIVATIVES AND USE THEREOF IN RADIATION THERAPY AND DIAGNOSTIC IMAGING | ⤷ Try a Trial |
| Ireland | 902299 | ⤷ Try a Trial | |
| Norway | 179203 | ⤷ Try a Trial | |
| Austria | 115546 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EOVIST
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0405704 | 300182 | Netherlands | ⤷ Try a Trial | 300182, 20100627, EXPIRES: 20150626 |
| 0405704 | SPC/GB05/021 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GADOXETIC ACID, OPTIONALLY IN THE FORM OF A SALT; REGISTERED: SE 18929 20040326; SE 18930 20040326; UK PL 00053/0348 20041110; UK PL 00053/0349 20041110 |
| 0405704 | 16/2005 | Austria | ⤷ Try a Trial | PRODUCT NAME: GADOXETSAEURE DINATRIUM; NAT. REGISTRATION NO/DATE: 1-25757, 1-25758 20050302; FIRST REGISTRATION: SE 18929, 18930 20040326 |
| 0405704 | C300182 | Netherlands | ⤷ Try a Trial | PRODUCT: GADOXETINEZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER HET NATRIUMZOUT. FIRST AUTHORIZATION NO/DATE: 1829 AND 18930, 20040326 (SE); NATIONAL AUTHORIZATION NO/DATE: RVG 31393 AND 31394, 20050113 |
| 0405704 | C00405704/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
